Delivery Order SPE2DB22D3301-SPE2DB25FY9PY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $10,662.57. The order is scheduled for completion by September 2, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The place of performance is...
- The Defense Logistics Agency awarded a $21,325.14 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price contract with an ultimate completion date of October 9, 2025. The award represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $31,987.71. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating that AmerisourceBergen Drug Corp...
- The Defense Logistics Agency awarded a $10,662.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tagrisso 80 mg tablets (30-count units) on August 15, 2025, with completion targeted for September 8, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $31,987.71 delivery order to AmerisourceBergen Drug Corp for 30-tablet units of Tagrisso 80 mg tablets under a firm fixed price contract. This delivery order, issued on September 25, 2025, with an ultimate completion date of October 17, 2025, represents a non-competitive set-aside award to the pharmaceutical distributor. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packages) with a ceiling value of $21.3K. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is scheduled for completion by October 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $31,987.71 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by October 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, consistent...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $10,662.57 on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 7, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY9PYDelivery Order
The Defense Logistics Agency awarded a $10,662.57 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tagrisso 80 mg tablets (30-unit package). This contract represents a competitive, firm fixed-price procurement with no set-aside designation and a completion date of September 10, 2025. The award is executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical commodities to military healthcare systems and other federal agencies worldwide. Tagrisso, an oncology treatment, represents the type of specialty pharmaceutical product within AmerisourceBergen's expansive therapeutic portfolio delivered through this flexible contracting vehicle to support Defense Health Agency and other government healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 8/19/25 |